Plasma membrane-coated nanoparticles (MNPs) have been used in various applications, including delivery of therapeutic agents and induction of immune responses et al. Unlike the conventional strategies, MNPs directly leverage intact and natural functions of cell membranes, and show high biocompatibility, specificity, and low side effects. DIMA biotech developed an optimized MNPs platform for the full-length membrane protein productions using membrane coating technology and HEK293 based expression platform. The high-purity plasma membrane-coated nanoparticles were produced by extrusion after membrane extraction from the host HEK293 cells containing the overexpressed target proteins.